Vericel Corp Ord Stock Alpha and Beta Analysis
| VCEL Stock | USD 52.52 0.19 0.36% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vericel Corp Ord. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vericel Corp over a specified time horizon. Remember, high Vericel Corp's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vericel Corp's market risk premium analysis include:
Beta 1.06 | Alpha (0) | Risk 2.05 | Sharpe Ratio (0.08) | Expected Return (0.15) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Vericel |
Vericel Corp Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vericel Corp market risk premium is the additional return an investor will receive from holding Vericel Corp long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vericel Corp. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vericel Corp's performance over market.| α | -0.0031 | β | 1.06 |
Vericel Corp expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vericel Corp's Buy-and-hold return. Our buy-and-hold chart shows how Vericel Corp performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vericel Corp Market Price Analysis
Market price analysis indicators help investors to evaluate how Vericel Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vericel Corp shares will generate the highest return on investment. By understating and applying Vericel Corp stock market price indicators, traders can identify Vericel Corp position entry and exit signals to maximize returns.
Vericel Corp Return and Market Media
The median price of Vericel Corp for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 57.55 with a coefficient of variation of 3.3. The daily time series for the period is distributed with a sample standard deviation of 1.89, arithmetic mean of 57.4, and mean deviation of 1.39. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Hopper Jonathan Mark of 10000 shares of Vericel Corp at 16.66 subject to Rule 16b-3 | 12/02/2024 |
2 | Disposition of 2600 shares by Wotton Paul K of Vericel Corp at 58.72 subject to Rule 16b-3 | 12/04/2024 |
3 | Vericel Corp Announces Strong 2024 Financial Results and Optimistic 2025 Outlook | 01/14/2025 |
4 | Vericel Corporation Provides Preliminary 2024 Financial Results and Updates Corporate Presentation | 01/15/2025 |
5 | Disposition of 08 shares by Jonathan Siegal of Vericel Corp at 61.99 subject to Rule 16b-3 | 01/28/2025 |
6 | Acquisition by Jonathan Siegal of 08 shares of Vericel Corp at 48.8 subject to Rule 16b-3 | 01/30/2025 |
7 | Vericel price target raised by 3 at Canaccord, heres why VCEL | 02/03/2025 |
8 | Vericel Strengthening Its Position in the Biopharmaceutical Market | 02/05/2025 |
9 | Disposition of 2500 shares by Zerbe Robert L Md of Vericel Corp at 60.0 subject to Rule 16b-3 | 02/07/2025 |
10 | Tissue Engineering Market Worth US8.9 billion by 2028 MarketsandMarkets | 02/10/2025 |
11 | Acquisition by Rubino Alan L of 15000 shares of Vericel Corp at 3.74 subject to Rule 16b-3 | 02/11/2025 |
12 | Acquisition by Mclaughlin Kevin F of 6000 shares of Vericel Corp at 3.74 subject to Rule 16b-3 | 02/12/2025 |
13 | Insider Trading | 02/13/2025 |
14 | Acquisition by Jonathan Siegal of 420 shares of Vericel Corp subject to Rule 16b-3 | 02/18/2025 |
15 | Acquisition by Colangelo Dominick of 73000 shares of Vericel Corp subject to Rule 16b-3 | 02/20/2025 |
16 | Acquisition by Jonathan Siegal of 6600 shares of Vericel Corp at 54.31 subject to Rule 16b-3 | 02/24/2025 |
About Vericel Corp Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vericel or other stocks. Alpha measures the amount that position in Vericel Corp Ord has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 3.22 | 2.77 | 2.49 | 1.94 | Days Of Inventory On Hand | 106.91 | 77.12 | 88.69 | 84.25 |
Vericel Corp Upcoming Company Events
As portrayed in its financial statements, the presentation of Vericel Corp's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vericel Corp's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vericel Corp's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vericel Corp. Please utilize our Beneish M Score to check the likelihood of Vericel Corp's management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Vericel Corp
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Vericel Corp Backtesting, Vericel Corp Valuation, Vericel Corp Correlation, Vericel Corp Hype Analysis, Vericel Corp Volatility, Vericel Corp History and analyze Vericel Corp Performance. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Vericel Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.